CureVac N.V.

BIT:1CVAC Stock Report

Market Cap: €924.0m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

CureVac Valuation

Is 1CVAC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 1CVAC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 1CVAC (€3.48) is trading below our estimate of fair value (€22.33)

Significantly Below Future Cash Flow Value: 1CVAC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1CVAC?

Key metric: As 1CVAC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1CVAC. This is calculated by dividing 1CVAC's market cap by their current earnings.
What is 1CVAC's PE Ratio?
PE Ratio7.2x
Earnings€128.82m
Market Cap€923.98m

Price to Earnings Ratio vs Peers

How does 1CVAC's PE Ratio compare to its peers?

The above table shows the PE ratio for 1CVAC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.5x
PHIL Philogen
18.8x-78.55%€861.7m
ARBS Arterra Bioscience
14.9xn/a€20.0m
9966 Alphamab Oncology
33.8xn/aHK$8.9b
ALVO Alvotech
18.6x33.56%US$1.3b
1CVAC CureVac
7.2x4.25%€1.1b

Price-To-Earnings vs Peers: 1CVAC is good value based on its Price-To-Earnings Ratio (7.2x) compared to the peer average (24.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 1CVAC's PE Ratio compare vs other companies in the European Biotechs Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
1CVAC 7.2xIndustry Avg. 17.7xNo. of Companies7PE020406080100+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1CVAC is good value based on its Price-To-Earnings Ratio (7.2x) compared to the European Biotechs industry average (16.9x).

Price to Earnings Ratio vs Fair Ratio

What is 1CVAC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1CVAC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.2x
Fair PE Ratio24x

Price-To-Earnings vs Fair Ratio: 1CVAC is good value based on its Price-To-Earnings Ratio (7.2x) compared to the estimated Fair Price-To-Earnings Ratio (24x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1CVAC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€4.61
0%
4.42%€4.75€4.32n/a3
Feb ’27n/a
€4.61
0%
4.42%€4.75€4.32n/a3
Jan ’27€3.76
€4.61
+22.43%
4.42%€4.75€4.32n/a3
Dec ’26€4.53
€4.61
+1.82%
4.42%€4.75€4.32n/a3
Nov ’26€4.61
€4.56
-1.22%
3.70%€4.69€4.32n/a3
Oct ’26€4.59
€4.60
+0.22%
3.52%€4.72€4.32n/a4
Sep ’26€4.57
€4.60
+0.53%
3.52%€4.72€4.32n/a4
Aug ’26€4.65
€4.61
-0.73%
3.72%€4.75€4.32n/a4
Jul ’26€4.58
€3.67
-19.85%
23.83%€4.72€2.59n/a4
Jun ’26€3.99
€5.53
+38.63%
59.53%€10.59€1.78n/a6
May ’26€3.24
€5.47
+69.07%
61.01%€10.59€2.20n/a6
Apr ’26€2.57
€6.91
+168.39%
73.82%€15.32€2.30n/a6
Mar ’26€2.95
€6.94
+135.48%
73.16%€15.32€2.36n/a6
Feb ’26€3.67
€6.90
+87.92%
72.82%€15.12€2.36n/a6
Jan ’26€2.96
€6.89
+133.04%
72.98%€15.12€2.36€3.766
Dec ’25€2.75
€6.89
+150.30%
72.98%€15.12€2.36€4.536
Nov ’25€2.60
€6.91
+165.21%
68.22%€14.43€2.35€4.616
Oct ’25€2.66
€6.51
+145.23%
68.57%€14.43€2.35€4.597
Sep ’25€2.85
€6.53
+129.62%
68.80%€14.56€2.35€4.577
Aug ’25€3.34
€7.01
+109.92%
70.22%€16.56€2.40€4.657
Jul ’25€3.17
€8.73
+175.37%
60.99%€16.63€2.43€4.587
Jun ’25€3.55
€8.72
+145.86%
61.11%€16.63€2.39€3.997
May ’25€2.37
€9.19
+288.14%
56.18%€16.84€2.43€3.247
Apr ’25€2.86
€12.50
+337.82%
43.16%€19.15€2.74€2.577
Mar ’25€3.21
€12.94
+303.87%
35.96%€19.15€5.83€2.957
Feb ’25€3.25
€12.92
+298.02%
35.99%€19.15€5.83€3.677
€3.85
Fair Value
9.5% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/17 10:51
End of Day Share Price 2025/12/17 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CureVac N.V. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas BuchananCitizens JMP Securities, LLC
Rajan SharmaGoldman Sachs
Eun Kyung YangJefferies LLC